Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ray Borrow

Showing results (301-310 of 403) with videos related to

Pageof 41
Sort By:
The Lancet. Infectious Diseases|March 23, 2024
Use of a meningococcal group B vaccine (4CMenB) in populations at high risk of gonorrhoea in the UKShamez N Ladhani, Peter J White, Helen Campbell, et al.
The Journal of Infection|June 7, 2020
The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccinationSydel R Parikh, Helen Campbell, Julie A Bettinger, et al.
The Journal of Experimental Medicine|May 28, 2008
A generic mechanism in Neisseria meningitidis for enhanced resistance against bactericidal antibodiesMaria Jose Uria, Qian Zhang, Yanwen Li, et al.
Vaccine|October 31, 2006
Immunogenicity and induction of immunological memory of the heptavalent pneumococcal conjugate vaccine in preterm UK infantsJens U Ruggeberg, Clare Collins, Paul Clarke, et al.
The Lancet. Infectious Diseases|January 11, 2021
Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trialKimberly Davis, Marta Valente Pinto, Nick J Andrews, et al.
Human Vaccines & Immunotherapeutics|April 13, 2021
High coverage of diverse invasive meningococcal serogroup B strains by the 4-component vaccine 4CMenB in Australia, 2007-2011: Concordant predictions between MATS and genetic MATSSarah J Tozer, Helen V Smith, David M Whiley, et al.
Open Forum Infectious Diseases|June 5, 2020
Immunogenicity and Reactogenicity of a Reduced Schedule of a 4-component Capsular Group B Meningococcal Vaccine: A Randomized Controlled Trial in InfantsMarta Valente Pinto, Daniel O'Connor, Ushma Galal, et al.
Vaccine|November 25, 2015
The current situation of meningococcal disease in Latin America and updated Global Meningococcal Initiative (GMI) recommendationsMarco Aurélio P Sáfadi, Miguel O'Ryan, Maria Teresa Valenzuela Bravo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 11, 2015
Meningococcal Seroepidemiology 1 Year After the PsA-TT Mass Immunization Campaign in Burkina FasoHaoua Tall, Seydou Yaro, Hervé B N Kpoda, et al.
Infection and Immunity|July 25, 2006
Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvacJamie Findlow, Stephen Taylor, Audun Aase, et al.
Pageof 41

Showing results (301-310 of 403) with videos related to

Sort By:
Pageof 41
The Lancet. Infectious Diseases|March 23, 2024
Use of a meningococcal group B vaccine (4CMenB) in populations at high risk of gonorrhoea in the UKShamez N Ladhani, Peter J White, Helen Campbell, et al.
The Journal of Infection|June 7, 2020
The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccinationSydel R Parikh, Helen Campbell, Julie A Bettinger, et al.
The Journal of Experimental Medicine|May 28, 2008
A generic mechanism in Neisseria meningitidis for enhanced resistance against bactericidal antibodiesMaria Jose Uria, Qian Zhang, Yanwen Li, et al.
Vaccine|October 31, 2006
Immunogenicity and induction of immunological memory of the heptavalent pneumococcal conjugate vaccine in preterm UK infantsJens U Ruggeberg, Clare Collins, Paul Clarke, et al.
The Lancet. Infectious Diseases|January 11, 2021
Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trialKimberly Davis, Marta Valente Pinto, Nick J Andrews, et al.
Human Vaccines & Immunotherapeutics|April 13, 2021
High coverage of diverse invasive meningococcal serogroup B strains by the 4-component vaccine 4CMenB in Australia, 2007-2011: Concordant predictions between MATS and genetic MATSSarah J Tozer, Helen V Smith, David M Whiley, et al.
Open Forum Infectious Diseases|June 5, 2020
Immunogenicity and Reactogenicity of a Reduced Schedule of a 4-component Capsular Group B Meningococcal Vaccine: A Randomized Controlled Trial in InfantsMarta Valente Pinto, Daniel O'Connor, Ushma Galal, et al.
Vaccine|November 25, 2015
The current situation of meningococcal disease in Latin America and updated Global Meningococcal Initiative (GMI) recommendationsMarco Aurélio P Sáfadi, Miguel O'Ryan, Maria Teresa Valenzuela Bravo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 11, 2015
Meningococcal Seroepidemiology 1 Year After the PsA-TT Mass Immunization Campaign in Burkina FasoHaoua Tall, Seydou Yaro, Hervé B N Kpoda, et al.
Infection and Immunity|July 25, 2006
Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvacJamie Findlow, Stephen Taylor, Audun Aase, et al.
Pageof 41